MiMedx Group Inc (MDXG.OQ)
20 Jul 2018
Thu, Jun 7 2018
Biotech firm MiMedx Group Inc replaced its chief financial officer on Thursday and said it would restate at least five years of financial statements following an internal investigation into sales and distribution practices, sending shares down as much as 30 percent.
* Co restates statements from fiscal 2012-2016, 3 quarters in 2017
June 7 Biotech MiMedx Group Inc said on Thursday it plans to restate certain financial statements and appointed Edward Borkowski as its interim chief financial officer.
* MIMEDX GROUP INC - COMMENTED ON INDICTMENT FILED IN COURT AGAINST INDIVIDUALS PREVIOUSLY EMPLOYED BY DEPARTMENT OF VETERANS AFFAIRS
Three healthcare providers with the U.S. Department of Veterans Affairs were indicted on charges they excessively used biotech MiMedx Group Inc's products on patients after accepting meals, trips and gratuities from the company.
May 9 Three healthcare providers with the U.S. Department of Veterans Affairs were indicted on charges they excessively used biotech MiMedx Group Inc's products on patients after accepting meals, trips and gratuities from the company.
* MIMEDX REPORTS UNREVIEWED FIRST QUARTER REVENUE EXCEEDED UPPER END OF ITS GUIDANCE
BRIEF-MiMedx Enrolls First Patient In Its Phase 2B Clinical Trial Of Amniofix® Injectable For Treatment Of Osteoarthritis Of The Knee
* MIMEDX ENROLLS FIRST PATIENT IN ITS PHASE 2B CLINICAL TRIAL OF RMAT DESIGNATED AMNIOFIX® INJECTABLE FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE Source text for Eikon: Further company coverage:
* MIMEDX REPORTS POSITIVE PAIN AND FOOT FUNCTION RESULTS FROM PHASE 2B CLINICAL TRIAL OF AMNIOFIX® INJECTABLE IN THE TREATMENT OF PLANTAR FASCIITIS
* MIMEDX ANNOUNCES EXPECTATION TO EXCEED THE $92 MILLION TOP END OF FIRST QUARTER REVENUE GUIDANCE